Although the award was much deserved, it was for work done when Frazer was not associated with Admedus - so although it offers reassurance of a greater probability of success, it is super shifty for a company to leverage off a past achievement of a current (key) employee. The only thing that will change market sentiment is continual positive announcements of company progress, i.e. Cardiocel sales, revenue growth, medical sales profits and successful trial outcomes.
Vote for Ian!, page-53
-
- There are more pages in this discussion • 36 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.00 |
Change
0.000(0.00%) |
Mkt cap ! $211.3M | |||
| Open | High | Low | Value | Volume |
| $10.00 | $10.00 | $9.80 | $96.66K | 9.794K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 286 | $9.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.99 | 198 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |